Chronic Lung Disease. Bronchitis, not specified as acute or chronic
Conditions
Interventions
Intervention 1: Intervention Group:
Aerosolized Budezonide is administered at 12 hours from birth and is continued each 12 hours for at most one week. Intervention 2: Control Group:
In this group, A
Treatment - Drugs
Treatment - Other
Intervention Group:
Aerosolized Budezonide is administered at 12 hours from birth and is continued each 12 hours for at most one week
Control Group:
In this group, Aerosolized Budesonide is not administered and the patients are just treated with nCPAP
Sponsors
Isfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
No minimum to 7 Days
Inclusion criteria
Inclusion criteria: Inclusion criteria: * 23 to 28 weeks gestational age. * compatible clinical symptoms of RDS (Respiratory Disease Syndrome) as (tachypnea, intercostal retraction, nasal flaring, grunting, and the need for supplemental oxygen). * letter of consent. Exclusion criteria: * congenital malformation. * prinatal asphyxia.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Chronic lung disease prevention. Timepoint: 4 weeks after birth. Method of measurement: The need for supplementary oxygen. | — |
Secondary
| Measure | Time frame |
|---|---|
| Reduction in need for surfactant. Timepoint: 72 hours after birth. Method of measurement: The need for supplementary oxygen more than 40%. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Alireza Sadeghnia
Isfahan University of Medical Sciences
Outcome results
None listed